Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
